Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) antibody] with or without tremelimumab [cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody], versus the EXTREME regimen in patients with R/M HNSCC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann Oncol

Title: Annals of oncology : official journal of the European Society for Medical Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1569-8041

ISSN (Print): 0923-7534

Publication date (Electronic): Mar 2023

Volume: 34

Issue: 3

Affiliations

[1 ] Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece. Electronic address: Psyrri237@yahoo.com.

[2 ] Centre de Lutte Contre le Cancer Léon Bérard, Lyon-I University, Lyon, France.

[3 ] Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK.

[4 ] Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

[5 ] Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.

[6 ] Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

[7 ] Division of Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, USA.

[8 ] Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

[9 ] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

[10 ] Department of General Physiology, Saint Petersburg State University, Saint Petersburg.

[11 ] Department of Oncology, Leningrad Regional Oncology Dispensary, Saint Petersburg.

[12 ] Budgetary Institution of Healthcare, Omsk Regional Oncology Dispensary, Omsk, Russian Federation.

[13 ] Division of Hematology & Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung City, Taiwan.

[14 ] Department of Medical Oncology, Healthcare Global Enterprises Limited, Bengaluru, Karnataka, India.

[15 ] Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain.

[16 ] Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy, Ukraine.

[17 ] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

[18 ] Department of Medical Oncology, West German Cancer Center, University Hospital, Essen.

[19 ] Department of Otolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany.

[20 ] Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK.

[21 ] Statistics, AstraZeneca, Gaithersburg, USA.

[22 ] Oncology R&D, Late-Stage Development, AstraZeneca, Gothenburg, Sweden.

[23 ] Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg.

[24 ] Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA. Electronic address: tseiwert@jhmi.edu.

Article

Publisher Item ID: S0923-7534(22)04778-0

DOI: 10.1016/j.annonc.2022.12.008

PubMed ID: 36535565

SO-VID: a640b019-716f-4a18-a7dd-db5eed0d61f5

History

Keywords: durvalumab,tremelimumab,programmed death-ligand 1,phase III study,immune checkpoint inhibition,head and neck squamous cell carcinoma

Data availability:

Keywords: durvalumab, tremelimumab, programmed death-ligand 1, phase III study, immune checkpoint inhibition, head and neck squamous cell carcinoma

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

Read this article at

Abstract

Related collections

Research from Ukraine

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 305

Cited by 14